

Effectiveness of Omicron XBB.1.5 vaccine against SARS-CoV-2 Omicron XBB and JN.1 infection in a prospective cohort study in the Netherlands, October 2023 to January 2024

Anne J. Huiberts (1), Christina E. Hoeve (1), Brechje de Gier (1), Jeroen Cremer (1), Bas van der Veer (1), Hester E. de Melker (1), Janneke H.H.M. van de Wijgert (1,2), Susan van den Hof (1), Dirk Eggink* (1), Mirjam J. Knol* (1)

1. Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
2. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht (UMCU), Utrecht, the Netherlands

* These authors contributed equally to this article and share last authorship.

Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95%CI:23-55) in 18-59-year-olds and 50% (95%CI:44-56) in 60-85-year-olds. Sequencing data in a subset of infections suggests immune escape of the emerging BA.2.86 (JN.1) variant from recent prior infection (OR:2.6; 95%CI:1.1-6.3) and, although not statistically significant, from XBB.1.5 vaccination (OR:1.6; 95%CI:0.9-2.9).

A monovalent mRNA vaccine targeting the SARS-CoV-2 Omicron XBB.1.5 subvariant (Comirnaty) was used in the 2023 Dutch COVID-19 vaccination campaign that started on October 2, 2023. Individuals aged ≥ 60 years, medical risk groups, pregnant women and healthcare workers were eligible for vaccination. Since September 2023, a new Omicron BA.2.86 sub-variant named JN.1 has emerged and quickly became dominant in the Netherlands and globally [1, 2]. BA.2.86 is genetically divergent from the previously circulating XBB variants, indicating potential for immune escape [3].

We estimated vaccine effectiveness (VE) of XBB.1.5 vaccination against self-reported SARS-CoV-2 infection between 9 October 2023 and 9 January 2024 among adults aged 18-85 years who had previously received primary vaccination and at least one booster vaccination before 2 October 2023 and were eligible for XBB.1.5 vaccination. To assess potential immune escape by JN.1, we analyzed whether there was an association between XBB.1.5 vaccination or prior infection and the Omicron variant causing the infection (XBB vs. BA.2.86, including JN.1). The variant was determined by sequencing of viral genetic material present in positive lateral flow antigen self-tests.

Study population

We used data from 23,895 participants of the VAccine Study COvid-19 (VASCO), an ongoing prospective cohort study among community-dwelling Dutch adults aged 18-85 years that started in May 2021 [4, 5]. Participants can report COVID-19 vaccinations and positive SARS-CoV-2 tests (PCR or lateral flow antigen (self-)test) any time. Participants provide self-collected fingerprick blood samples every 6 months for serological testing. Self-tests are provided to participants. For the current analysis, follow-up time started on 9 October 2023 and ended on either 9 January 2024, date of first positive SARS-CoV-2 test or date of last completed questionnaire, whichever occurred first. The seven person-days after XBB.1.5-vaccination were excluded. If participants reported a vaccination or infection in the three months prior to the XBB.1.5 vaccination campaign, follow-up started three months after this vaccination or infection.

Of 4,861 participants aged 18-59 years (XBB.1.5 vaccine-eligible because of being a healthcare worker or belonging to a medical risk group), 1,167 (24%) received XBB.1.5 vaccination during the follow-up period (**Table 1**). Of 19,034 participants aged 60-85 years (XBB.1.5 vaccine-eligible because of age), 11,330 participants (60%) received XBB.1.5 vaccination. In both age groups, XBB.1.5 vaccination recipients more often received a bivalent vaccination in the autumn 2022 COVID-19 vaccination campaign, compared to non-recipients (18-59-year-olds: 91% vs 56%; 60-85-year-olds: 93% vs 68%).

During follow-up, 1,951 SARS-CoV-2 infections were reported. Reported incidence increased during the study period (**Figure 1**), consistent with national syndromic and wastewater surveillance data [6, 7]. Those without prior infection, defined as no self-reported positive SARS-CoV-2 test and negative anti-Nucleoprotein serology (8% of 18-59-year-olds; 16% of 60-85-year-olds), had the highest incidence (note that 18-59-year-olds included low number of participants and infections; **Figure S1**). Incidence was lowest among those with a prior infection <1 year ago. Incidence was consistently lower among those with XBB.1.5 vaccination compared to those without regardless of prior infection history.

Vaccine effectiveness

VE was estimated using Cox proportional hazard models with calendar time as time scale, XBB.1.5-vaccination as time-varying exposure and adjustment for age group, sex, education level, medical risk condition and infection history. Analyses were performed using R version 4.3.2, packages Epi, survival and stats.

VE was 41% (95%CI:23-55) among 18-59-year-olds and 50% (95%CI:44-56) among 60-85-year-olds (**Figure 2, Table S1**). VE estimates were somewhat higher up to 6 weeks after vaccination compared to 7-12 weeks after vaccination among 60-85 year-olds (52% vs 41%), but CIs are wide. A sensitivity analysis among participants who, during the study period, reported to (almost) always test in case of symptoms showed a slightly higher VE of 45% (95%CI:26-59) among 18-59-year-olds and 54% (95%CI:47-59) among 60-85-year-olds (**Figure 2, Table S2**). When only known symptomatic infections (68% of the infections; 21% asymptomatic, 11% unknown) were included, VE was 35% among 18-59-year-olds and 55% among 60-85-year-olds.

Independent of infection history, XBB.1.5 vaccination provided additional protection in both 18-59-year-olds and 60-85-year-olds. Among 60-85-year-olds, protection against infection was highest after a prior infection <1 year ago either with (85%) or without (73%) XBB.1.5 vaccination (**Table S2**). This same trend was seen in 18-59-year-olds (87% and 61%, respectively).

Emerging subvariant

From June 2023, VASCO participants were asked to submit positive self-tests for sequencing. Residual viral genetic material was extracted from the test strips of the self-tests (as described by [8]), and sequenced if the RT-PCR reactions were positive, to determine the variant that caused the infection [9].

Of 3,525 reported infections between 9 October 2023 and 9 January 2024 (also including infections notified after completion of the last questionnaire and therefore excluded from the VE analysis), 764 self-tests with a strong positive band were sequenced (**Figure S2**). Of those, 530 resulted in (near) whole genome sequences. Identified variants were Omicron XBB (149;28%), Omicron BA.2.86 (370;70%), of which 314 (85%) were sub-variant JN.1, and other Omicron variants (11;2%). Infections caused by BA.2.86 increased from 13% in the first week of the study period to 100% in the last week (**Figure S3**). Observed prevalence of variants corresponded well with national SARS-CoV-2 genomic surveillance [10].

Among infected participants with sequencing data (**Table S3**), we performed logistic regression to estimate the association between XBB.1.5 vaccination or prior infection and the Omicron variant causing the infection (XBB and BA.2.86), adjusting for testing week, age group, sex, education level and medical risk condition. By adjusting for testing week, we compared XBB and BA.2.86 infections at the same moment in calendar time.

XBB.1.5 vaccinated participants had a non-significantly higher odds of their infection being caused by BA.2.86 rather than XBB (OR:1.6; 95%CI:0.9-2.9; **Table 2**), suggesting that the VE against BA.2.86 may be lower than the VE against XBB. Participants with a prior infection <1 year ago had a significantly higher odds of their infection being caused by BA.2.86 rather than XBB (OR:2.6; 95%CI:1.1-6.3), compared to participants without prior infection. No significant association was observed for participants with a prior infection >1 year ago (OR:1.4; 95%CI:0.7-2.5).

Discussion and conclusion

The VE of XBB.1.5 vaccination against self-reported SARS-CoV-2 infection among XBB.1.5 vaccine-eligible participants who had previously received a primary vaccination series and at least one booster vaccination was 41% for 18-59-year-olds and 50% for 60-85-year-olds, with similar estimates against symptomatic infection. Furthermore, irrespective of vaccination status, protection of a recent prior infection against a new infection was high. Protection from XBB.1.5 vaccination and recent prior infection seemed lower against BA.2.86 compared to XBB infection (OR of 1.6 (non-significant) and 2.6, respectively), suggesting immune escape by BA.2.86.

A recent study from the US reported comparable estimates against symptomatic infection of 57% in 18-49-year-olds and 46% in those aged ≥ 50 years [11]. Their VE estimates were considerably higher compared to their estimates during the 2022/2023 winter season of the bivalent booster vaccination (46%, 38% and 36% in individuals aged 18–49 years, 50–64 and ≥ 65 years, respectively) [12]. Also our estimates were considerably higher compared to our estimates of the bivalent booster: 31% in 18-59-year-olds and 14% in 60-85-year-olds [13]. This suggests that the 2023 XBB.1.5 vaccine better matches the virus that is circulating in the 2023/2024 winter season than the 2022 bivalent vaccine did in the 2022/2023 winter season, when Omicron BQ.1 and BA.2.75 were circulating in the Netherlands [10]. Possible alternative explanations for the higher VE compared to last year are the longer time period since prior vaccination campaigns and lower virus circulation in the summer of 2023. However, sensitivity analyses showed similar VEs among those who had received the bivalent vaccination, and after stratifying by infection history.

Preliminary immunological data suggest that BA.2.86 and JN.1 show modest signs of immune evasion to XBB.1.5 vaccination, but both strains were found to be neutralized by XBB.1.5 vaccine-induced antibodies [14, 15] and prior XBB infection [16]. A recent study from Denmark reported that XBB.1.5 vaccinated cases had a 1.6 times higher odds of their infection being caused by BA.2.86 than other variants compared to unvaccinated cases [17], which is consistent with our findings. Also, VE estimates of XBB.1.5 vaccination from the US were reported to be lower against infections caused by JN.1 (49%) than infections caused by XBB-related lineages (60%), although the difference was non-significant [11]. The apparent immunological advantage of the BA.2.86 sub-variant JN.1 may be the reason that it became dominant quickly, in contrast to different XBB subvariants that circulated simultaneously last year.

We provided participants with self-tests free-of-charge, thereby reducing bias associated with access to testing. However, we did rely on participant adherence to study instructions related to testing and reporting of infections, which could have influenced our estimates. However, restricting the analysis to participants with high test intention only slightly increased our estimates. Furthermore, serological data enabled us to detect and adjust for prior untested (asymptomatic) infections, but serology data were not available for all study participants (84-87% of participants in the past year). Furthermore, imputation of the infection date when an infection was detected by serology only may have resulted in misclassification of time since prior infection. Self-reported vaccination data was confirmed by linkage to vaccination registry data, limiting exposure misclassification.

Other studies have shown benefit of the XBB.1.5 vaccination campaign in reducing COVID-19 hospitalizations [18, 19]. We showed that XBB.1.5 vaccination also provided considerable protection against SARS-CoV-2 infection in the first three months post-vaccination. Recent prior infection also protects against new infection, but it should be kept in mind that experiencing a SARS-CoV-2 infection carries risk of severe disease in vulnerable groups, and of post-COVID condition. We found

indications of immune escape of the emerging BA.2.86 (JN.1) variant from XBB.1.5 vaccination and prior infection, possibly explaining the rapid increase of this variant worldwide.

References

1. Centers for Disease Control and Prevention. COVID-19 Activity Increases as Prevalence of JN.1 Variant Continues to Rise: Centers for Disease Control and Prevention,; 2024 [19 January 2024]. Available from: <https://www.cdc.gov/respiratory-viruses/whats-new/JN.1-update-2024-01-05.html>.
2. Looi M-K. Covid-19: WHO adds JN.1 as new variant of interest. BMJ. 2023;383:p2975.
3. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Alfredo A Hinay J, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant [PREPRINT]. bioRxiv 2023:2023.12.08.570782.
4. Huiberts A, Kooijman M, Melker H, Hahne S, Grobbee D, Hoeve C, et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO) [PREPRINT]. Research Square 2022.
5. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, den Hartog G, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. Int J Infect Dis. 2023;133:36-42.
6. Rijksoverheid. Coronadashboard: Virusdeeltjes in rioolwater. [8 January 2024]. Available from: <https://coronadashboard.government.nl/landelijk/rioolwater>.
7. Rijksinstituut voor Volksgezondheid en Milieu. Actuele resultaten Infectieradar [8 January 2024]. Available from: <https://www.infectieradar.nl/results>.
8. Rector A, Bloemen M, Schiettekatte G, Maes P, Van Ranst M, Wollants E. Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance? Euro Surveill. 2023;28(9).
9. Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nature Communications. 2022;13(1):4738.
10. Rijksinstituut voor Volksgezondheid en Milieu. Varianten van het coronavirus SARS-CoV-2 2023 [12 January 2024]. Available from: <https://www.rivm.nl/coronavirus-covid-19/virus/varianten>.
11. Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024;73(4):77-83.
12. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-30.
13. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJ, den Hartog G, et al. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Euro Surveill. 2023;28(7).
14. Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, et al. Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine [PREPRINT]. bioRxiv. 2023:2023.11.17.567633.
15. Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants [PREPRINT]. bioRxiv. 2023:2023.11.26.568730.
16. Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023;624(7992):639-44.

17. Moustsen-Helms IR, Bager P, Graakjær Larsen T, Møller FT, Skafte Vestergaard L, Engbo Christiansen L, et al. Relative Vaccine Protection, Disease Severity and Symptoms Associated with Infection with SARS-CoV-2 Omicron Subvariant Ba.2.86 and Descendent Jn.1: A Danish Nationwide Register-Based Study [PREPRINT]. SSRN. 2024.
18. Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. *The Lancet Infectious Diseases*. 2024.
19. van Werkhoven CH, Valk A-W, Smagge B, de Melker HE, Knol MJ, Hahné SJ, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. *Eurosurveillance*. 2024;29(1):2300703.

Table 1. Characteristics of included VASCO participants vaccinated with primary series, at least one booster dose and eligible for XBB.1.5 vaccination

	18-59 years						60-85 years					
	Total		Without XBB.1.5 vaccination		With XBB.1.5 vaccination		Total		Without XBB.1.5 vaccination		With XBB.1.5 vaccination	
	n	%	n	%	n	%	n	%	n	%	n	%
All participants ^a	4861	100	3694	100	1167	100	19031	100	7704	100	11,330	100
Age (years) (median; IQR)	51 (14)		51 (14)		52 (12)		66 (6)		65 (6)		67 (6)	
Gender												
Female	4034	83.0	3060	82.8	974	83.5	10623	55.8	4524	58.7	6099	53.8
Male	823	16.9	632	17.1	191	16.4	8411	44.2	3180	41.3	5231	46.2
Other	4	0.1	2	0.1	2	0.2	0	0	0	0	0	0
Medical risk condition ^b , yes	2688	55.3	1992	53.9	696	59.6	8179	43.0	3075	39.9	5104	45.0
Cardiovascular disease	889	18.3	659	17.8	230	19.7	4920	25.8	1805	23.4	3115	27.5
Lung disease or asthma	869	17.9	588	15.9	281	24.1	1470	7.7	520	6.7	950	8.4
Diabetes mellitus	246	5.1	163	4.4	83	7.1	1229	6.5	450	5.8	779	6.9
Immune deficiency	205	4.2	146	4.0	59	5.1	307	1.6	124	1.6	183	1.6
Healthcare worker, yes	2832	58.3	2156	58.4	676	57.9	2106	11.1	985	12.8	1121	9.9
Education level ^c												
High	2995	61.6	2222	60.2	773	66.2	10193	53.6	3779	49.1	6414	56.6
Intermediate	1583	32.6	1237	33.5	346	29.6	5125	26.9	2254	29.3	2871	25.3
Low	262	5.4	215	5.8	47	4.0	3577	18.8	1615	21.0	1962	17.3
Other	21	0.4	20	0.5	1	0.1	139	0.7	56	0.7	83	0.7
Bivalent booster in autumn 2022 vaccination campaign (started on 19 September 2022)												
Yes	3121	64.2	2062	55.8	1059	90.7	15799	83.0	5222	67.8	10577	93.4
No	1740	35.8	1632	44.2	108	9.3	3235	17.0	2482	32.2	753	6.6
Time since last booster vaccination at start study follow-up (weeks) (median; IQR)	51.7 (41)		52.6 (42)		50.7 (3)		50.7 (3)		50.9 (16)		50.6 (3)	
Infection history ^d												
No prior infection	399	8.2	268	7.3	131	11.2	3130	16.4	1184	15.4	1946	17.2
Infection > 1 year ago	2973	61.2	2302	62.3	671	57.5	10558	55.5	4341	56.3	6217	54.9
Infection < 1 year ago	1489	30.6	1124	30.4	365	31.3	5346	28.1	2179	28.3	3167	28.0
Test intention (% (almost) always testing when having symptoms)	3614	74.3	2668	72.2	946	81.1	16604	87.2	6551	85.0	10053	88.7
Most recent serological data ^e												
<1 year prior to start follow-up	4106	84.5	3111	84.2	995	85.3	16465	86.5	6666	86.5	9799	86.5
>1 year prior to start follow-up	700	14.4	541	14.6	159	13.6	2283	11.9	908	12.0	1375	12.1
No serological data available	55	1.1	42	1.1	13	1.1	286	1.5	130	1.7	156	1.4

^a Participants who had previously received primary vaccination series and at least one booster vaccination and were eligible for XBB.1.5 vaccination (aged ≥60 years, medical risk groups, and healthcare workers). Participants who received a third dose before the start of the first general public booster campaign (18 November 2021) were excluded.

^b Medical risk condition: one or more of following conditions: diabetes mellitus, lung disease or asthma, asplenia, cardiovascular disease, immune deficiency, cancer (currently untreated, currently treated, untreated), liver disease, neurological disease, renal disease, organ or bone marrow transplantation.

^c Educational level was classified as low (no education or primary education), intermediate (secondary school or vocational training), or high (bachelor's degree, university).

^d Most recent prior infection based on self-reported positive SARS-CoV-2 tests and anti-Nucleoprotein-antibodies. When based on anti-Nucleoprotein-antibodies (no corresponding infection reported) infection date was imputed as mid-date between two blood samples, where the first was negative and the second was positive for N-antibodies, or where the second had at least a four-fold increase in N-antibody concentration compared to the first. When the first serum sample of a participant was positive for N-antibodies but no prior infection was reported, an infection date was imputed as the mid-date between the baseline questionnaire and sample receipt.

^e Most recent fingerprick blood sample for which anti-Nucleoprotein-antibodies could be determined. Participants are requested to take a fingerprick blood sample every six months during follow-up.

Figure 1. 14-day moving average of the number of reported infections per 100,000 participants in the period 9 October 2023 to 9 January 2024, by infection history and age group





Figure 2. Vaccine effectiveness^a and 95% confidence interval of XBB.1.5 vaccine against Omicron infection in the period 9 October 2023 to 9 January 2024 among participants vaccinated with primary series and at least one booster and eligible for XBB.1.5 vaccination stratified by age group



^a Adjusted for age group (18-39, 40-59, 60-69, 70-85 years), sex, education level, presence of a medical risk condition and infection history

Table 2. Association between XBB.1.5 vaccination status and SARS-CoV-2 BA.2.86 vs XBB infection, in the period 9 October 2023 to 9 January 2024

	XBB infection		BA.2.86 infection		Adjusted ^a OR (95% CI)
	n	%	n	%	
XBB.1.5 vaccination status					
Without XBB.1.5 vaccination	118	79.2	173	46.8	Reference
With XBB.1.5 vaccination	31	20.8	197	53.2	1.6 (0.9-2.9)
Infection history					
No prior infection	35	23.5	65	17.6	Reference
Infection >1 year ago	98	65.8	229	61.9	1.4 (0.7-2.5)
Infection <1 year ago	16	10.7	76	20.5	2.6 (1.1-6.3)

^a Adjusted for testing week, age group (18-39, 40-59, 60-69, 70-85), sex, education level and presence of a medical risk condition

